Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nuria Kotecki

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Current Opinion in Oncology|July 19, 2016
Inappropriate dose of multitargeted tyrosine kinase inhibitors: the original sinNuria Kotecki, Nicolas Penel
Current Opinion in Oncology|July 24, 2019
Checkpoints inhibitors in the (neo)adjuvant setting of solid tumors: lessons learnt and perspectivesNuria Kotecki, Ahmad Awada
Bulletin Du Cancer|March 21, 2017
[Bipolar disorders in oncology: Characteristics and management]Michel Reich, Nuria Kotecki
Current Opinion in Oncology|July 14, 2017
How to emerge from the conservatism in clinical research methodology?Nuria Kotecki, Nicolas Penel, Ahmad Awada
Current Opinion in Oncology|March 3, 2015
Metabolic disorders associated with the use of targeted cancer therapiesNuria Kotecki, Nicolas Penel, Ahmad Awada
Current Opinion in Oncology|July 20, 2022
Molecular oncology: what is needed to speed access to innovative therapies in clinical research?Karim Gourari, Ahmad Awada, Nuria Kotecki
Current Opinion in Oncology|August 16, 2020
Targeting molecular subtypes in solid cancers: successes and failuresRita Assi, Nuria Kotecki, Ahmad Awada
Current Opinion in Oncology|August 8, 2023
Preclinical models to understand the biology and to discover new targets in brain metastasesNadège Kindt, Nuria Kotecki, Ahmad Awada
Current Opinion in Oncology|July 26, 2021
New horizons in early drugs development in solid cancersNuria Kotecki, Nadège Kindt, Mohammad Krayem, et al.
Bulletin Du Cancer|November 25, 2015
[Factitious diseases in oncology]Michel Reich, Amélie Clermont, Éric Amela, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Current Opinion in Oncology|July 19, 2016
Inappropriate dose of multitargeted tyrosine kinase inhibitors: the original sinNuria Kotecki, Nicolas Penel
Current Opinion in Oncology|July 24, 2019
Checkpoints inhibitors in the (neo)adjuvant setting of solid tumors: lessons learnt and perspectivesNuria Kotecki, Ahmad Awada
Bulletin Du Cancer|March 21, 2017
[Bipolar disorders in oncology: Characteristics and management]Michel Reich, Nuria Kotecki
Current Opinion in Oncology|July 14, 2017
How to emerge from the conservatism in clinical research methodology?Nuria Kotecki, Nicolas Penel, Ahmad Awada
Current Opinion in Oncology|March 3, 2015
Metabolic disorders associated with the use of targeted cancer therapiesNuria Kotecki, Nicolas Penel, Ahmad Awada
Current Opinion in Oncology|July 20, 2022
Molecular oncology: what is needed to speed access to innovative therapies in clinical research?Karim Gourari, Ahmad Awada, Nuria Kotecki
Current Opinion in Oncology|August 16, 2020
Targeting molecular subtypes in solid cancers: successes and failuresRita Assi, Nuria Kotecki, Ahmad Awada
Current Opinion in Oncology|August 8, 2023
Preclinical models to understand the biology and to discover new targets in brain metastasesNadège Kindt, Nuria Kotecki, Ahmad Awada
Current Opinion in Oncology|July 26, 2021
New horizons in early drugs development in solid cancersNuria Kotecki, Nadège Kindt, Mohammad Krayem, et al.
Bulletin Du Cancer|November 25, 2015
[Factitious diseases in oncology]Michel Reich, Amélie Clermont, Éric Amela, et al.
Pageof 4